More Phase 3 disappointment in Alzheimer’s disease
Alzheimer's underdog Accera revealed Tuesday that its 413-patient trial of AC-1204 failed to reach its stated endpoints.
Alzheimer's underdog Accera revealed Tuesday that its 413-patient trial of AC-1204 failed to reach its stated endpoints.